176 related articles for article (PubMed ID: 38677307)
1. Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE.
Black DM; Thompson AR; Eastell R; Bouxsein ML
Lancet Diabetes Endocrinol; 2024 Jun; 12(6):371-373. PubMed ID: 38677307
[No Abstract] [Full Text] [Related]
2. Treatment failure in osteoporosis.
Diez-Perez A; Adachi JD; Agnusdei D; Bilezikian JP; Compston JE; Cummings SR; Eastell R; Eriksen EF; Gonzalez-Macias J; Liberman UA; Wahl DA; Seeman E; Kanis JA; Cooper C;
Osteoporos Int; 2012 Dec; 23(12):2769-74. PubMed ID: 22836278
[TBL] [Abstract][Full Text] [Related]
3. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
4. Review of the guideline of the American College of Physicians on the treatment of osteoporosis.
Kanis JA; Cooper C; Rizzoli R; Reginster JY
Osteoporos Int; 2018 Jul; 29(7):1505-1510. PubMed ID: 29869039
[TBL] [Abstract][Full Text] [Related]
5. Monitoring strontium ranelate therapy in patients with osteoporosis.
Kendler DL; Adachi JD; Josse RG; Slosman DO
Osteoporos Int; 2009 Jul; 20(7):1101-6. PubMed ID: 19266136
[TBL] [Abstract][Full Text] [Related]
6. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials.
Black DM; Bauer DC; Vittinghoff E; Lui LY; Grauer A; Marin F; Khosla S; de Papp A; Mitlak B; Cauley JA; McCulloch CE; Eastell R; Bouxsein ML;
Lancet Diabetes Endocrinol; 2020 Aug; 8(8):672-682. PubMed ID: 32707115
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of pharmacologic treatments to prevent fractures: is this all we need to know?
Bischoff-Ferrari HA; Meyer O
Ann Intern Med; 2014 Nov; 161(10):755-6. PubMed ID: 25199999
[No Abstract] [Full Text] [Related]
8. Bisphosphonates for osteoporosis in people with cystic fibrosis.
Conwell LS; Chang AB
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD002010. PubMed ID: 24627308
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates for osteoporosis in people with cystic fibrosis.
Conwell LS; Chang AB
Cochrane Database Syst Rev; 2012 Apr; (4):CD002010. PubMed ID: 22513903
[TBL] [Abstract][Full Text] [Related]
10. Summary for Patients: Pharmacologic Treatment of Primary Osteoporosis or Low Bone Mass to Prevent Fractures in Adults.
Ann Intern Med; 2023 Feb; 176(2):I24. PubMed ID: 36592458
[No Abstract] [Full Text] [Related]
11. Therapies for Preventing Bone Loss with Glucocorticoid Treatment.
Agarwal A; Adachi JD
Curr Osteoporos Rep; 2021 Feb; 19(1):34-39. PubMed ID: 33409989
[TBL] [Abstract][Full Text] [Related]
12. [New bone density conservation agents for osteoporosis under research and development: ED-71].
Hagino H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():454-8. PubMed ID: 18161148
[No Abstract] [Full Text] [Related]
13. Screening for Osteoporosis to Prevent Fractures: Recommendation Statement.
Am Fam Physician; 2018 Nov; 98(10):Online. PubMed ID: 30365294
[No Abstract] [Full Text] [Related]
14. Bone Mineral Density Loss and Fracture Risk After Discontinuation of Anti-osteoporotic Drug Treatment: A Narrative Review.
Elbers LPB; Raterman HG; Lems WF
Drugs; 2021 Sep; 81(14):1645-1655. PubMed ID: 34524681
[TBL] [Abstract][Full Text] [Related]
15. [New bone density conservation agents for osteoporosis under research and development: Strontium ranelate].
Shiraki M
Nihon Rinsho; 2007 Nov; 65 Suppl 9():447-53. PubMed ID: 18161147
[No Abstract] [Full Text] [Related]
16. [Efficacy and safety of long-term bisphosphonate treatment for osteoporosis.].
Miki T
Clin Calcium; 2017; 27(2):239-246. PubMed ID: 28123126
[TBL] [Abstract][Full Text] [Related]
17. Osteoporosis in men: update 2011.
Orwig DL; Chiles N; Jones M; Hochberg MC
Rheum Dis Clin North Am; 2011 Aug; 37(3):401-14, vi. PubMed ID: 22023899
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review.
Peppone LJ; Hebl S; Purnell JQ; Reid ME; Rosier RN; Mustian KM; Palesh OG; Huston AJ; Ling MN; Morrow GR
Osteoporos Int; 2010 Jul; 21(7):1133-49. PubMed ID: 19960185
[TBL] [Abstract][Full Text] [Related]
19. Letter to the Editor: A Possible Mechanism of Denosumab Treatment for Fracture Prevention.
Sugiyama T; Kim YT; Oda H
J Clin Endocrinol Metab; 2016 Feb; 101(2):L15-6. PubMed ID: 26840106
[No Abstract] [Full Text] [Related]
20. Summary for Patients: Fracture Risk During Osteoporosis Drug Holidays.
Ann Intern Med; 2022 Mar; 175(3):I23. PubMed ID: 35007145
[No Abstract] [Full Text] [Related]
[Next] [New Search]
